Michael Hawker is a Non-Executive Director of Aviva Plc Group (UK), the Macquarie Group Limited, Macquarie Bank Limited and Washington H. Soul Pattinson. Michael is Chair of the Australian Business and Community Network Foundation, a Non-Executive Director of the Rugby World Cup Limited. His former Executive roles include Chair of the Australian Rugby Union, Non-Executive Director of SANZAR Pty Limited, Member of the Executive Committee, World Rugby Council, CEO and Managing Director of Insurance Australia Group, Group Executive of Business and Consumer Banking at Westpac, Executive Director of Citibank International in Europe, and a Deputy Managing Director of Citibank in Australia. He has been President of the Insurance Council of Australia and the Australian Financial Markets Association, a former Board member of The Geneva Association and a former member of the Financial Sector Advisory Council. He is a Senior Fellow of the Financial Services Institute of Australia and a Fellow of the Australian Institute of Company Directors. Michael joined the Board in February 2011.

Yasmin Allen is a non-executive director of Cochlear Limited, Chairman of its Audit Committee and a member of Cochlear’s technology committee. She is also a non-executive director of ASX Limited, member of the ASX Audit Committee and ASX Clearing and Settlement board. Yasmin is a director at Santos Limited and a member of Santos’ Remuneration Committee and Environment, Health and Saftey Committee. She is also a director of the National Portrait Gallery.

Yasmin's previous directorships include Insurance Australia Group Limited (IAG) where she was Chairman of IAG’s Nomination and Remuneration Committee and a member of its Audit and Risk Committee. Yasmin was also Chairman of Macquarie Global Infrastructure Funds and a National Director of the Australian Institute of Company Directors. 

Prior to her directorships, Yasmin had an extensive career in investment banking, including as Vice President of Deutsche Bank, Director of ANZ Investment Bank in Sydney and Director with HSBC in London. She has a Bachelor of Commerce from Melbourne University and in 2015 was awarded their Alumni of Distinction Award. She is a Fellow of the Australia Institute of Company Directors and a member (and former council member) of Chief Executive Women. Yasmin joined the board in August 2014.

David Armstrong is a Non-Executive Director of the National Australia Bank (since August 2014). Chair of the Risk Committee and a member of its Audit Committee and Information Technology Committee. David is also a Director of the Opera Australia Capital Fund Limited (since May 2013), and a Trustee of the Australian Museum (since January 2014) and Lizard Island Reef Research Foundation (since April 2014). David has more than 30 years’ experience in professional services. As a Chartered Accountant and a former partner of PricewaterhouseCoopers, he has significant knowledge and understanding of banking and capital markets, real estate and infrastructure and is well versed in reporting, regulatory and risk challenges faced by the industry. David has lived and worked in London and New York at various stages of his career. David is a Fellow of the Institute of Chartered Accountants in Australia and a member of the Australian Institute of Company Directors. David joined the Board in October 2014, and is Chair of its Finance, Risk and Audit Committee. 

Paul McClintock is Chairman of Myer Holdings Limited, NSW Ports, I-MED Network, Sydney Health Partners, the Committee for Economic Development of Australia, and a Director of St Vincent’s Health Australia Limited. Paul has served as the Secretary to Cabinet and Head of the Cabinet Policy Unit reporting directly to the Prime Minister as Chairman of Cabinet, supervising Cabinet processes and acting as the Prime Minister’s most senior personal policy adviser. Former positions include Chairman of Medibank Private Limited, Thales Australia, the COAG Reform Council, Intoll Management Limited, Symbion Health, Affinity Health, Ashton Mining, Plutonic Resources and the Woolcock Institute of Medical Research. Paul graduated in Arts and Law from the University of Sydney and is an Honorary Fellow of the Faculty of Medicine. Paul joined the Board in October 2013.

Srinivas Akkaraju is a former General Partner of Sofinnova Ventures. Prior to Sofinnova, Srini was a Managing Director of New Leaf Venture Partners, and prior to that, a Founding Managing Director at Panorama Capital, LLC., a prior to that, a Partner with J.P. Morgan Partners. Before his investment career, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Dr Akkaraju currently serves as a Director of Intercept Pharmaceuticals, Inc., Seattle Genetics, Versartis Inc., and aTyr Pharma, Inc. Previously, Dr. Akkaraju served as a director on the boards of ZS Pharma, Inc., Eyetech Pharmaceuticals, Inc., Synageva Biopharma Corp., Barrier Therapeutics, Inc., and Amarin Corporation plc. Srinivas joined the Board February 2016.

Robyn Norton is co-founder and Principal Director of The George Institute for Global Health. She is Professor of Global Health & Oxford Martin Senior Fellow, University of Oxford; Professor of Public Health, Faculty of Medicine, UNSW Sydney; and Honorary Professor at Peking University. 

Professor Norton has published widely and is internationally regarded for her research on the causes, prevention and management of injuries, especially road traffic and fall-related injuries, as well as the management of various critical conditions in surgical and intensive care settings. She was the inaugural Chair and is now Chair Emeritus of the Road Traffic Injuries Research Network, a network supported by the World Bank and the WHO, aimed at building research capacity and research agendas, to address the growing burden of road traffic injuries in low and middle income countries.

She has had a long-standing commitment to improving women’s health and currently leads The George Institute’s research, implementation and advocacy efforts, aimed at improving the health of women and girls worldwide. Most recently she was the lead author on a University of Oxford supported policy paper entitled “Women’s Health: A New Global Agenda”, calling for a greater focus on addressing the burden of non-communicable diseases in women and the importance of a gendered approach to the collection and utilisation of health data.